Bristol Myers, yielding to FDA pressure, pulls Opdivo in post-Nexavar liver cancer
Amid a regulatory campaign targeting immuno-oncology agents, Bristol Myers Squibb figured it’s probably futile to keep fighting the FDA on Opdivo’s shaky use in previously treated liver cancer. On Friday, Bristol Myers said it’s voluntarily withdrawing Opdivo’s approval in hepatocellular carcinoma patients who previously received Bayer’s standard-of-care Nexavar. The decision came about three months after… Read More »